Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Do I have this largely correct?

<< Previous

Bullboard Posts

Next >>

Comment by jfm1330on Jun 06, 2023 8:00pm

141 Views

Post# 35483476

RE:RE:RE:Do I have this largely correct?

Thanks. As I said to SPCEO, my part is just to be willing to try it and suffer poorer quality of life, after that it is luck more than anything else. This chemo is not approved for my exact cancer type, but a small study showed 25% of patients with my type of cancer are reacting positively to it for a while. My oncologist told me she has a patient that is on this chemo for the last four years now, and that his tumors are still slowly shrinking after four years, but this guy is the very lucky one. It's probably why she told me not to expect spectacular results after four months, if any.